bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-31-0774-01

Order Name:
Lyme Disease Antibody, Immunoblot (MAYO Lab-USA) **

 
Useful For:
Aids in the diagnosis of systemic Lyme disease
 
Methodology:
Immunoblot Microarray
 
AliasesName:
Lyme Disease Antibody, Western Blot Assay, Serum
 
 
 
Test Code:
090-31-0774-01

Order Name:
Lyme Disease Antibody, Immunoblot (MAYO Lab-USA) **

 
Patient Preparation:
N/A 
 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 1 mL x 2 tubes
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Other Heat-inactivated specimen
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum Refrigerated, 2oC to 8oC (preferred)     14 days  
Frozen   30 days  
 
 
 
Test Code:
090-31-0774-01

Order Name:
Lyme Disease Antibody, Immunoblot (MAYO Lab-USA) **

 
Method detail:
Immunoblot Microarray
 
Schedule:
N/A **Sent out to MAYO, USA
 
Turnaround Time:
Received specimen to reported within 14 days
 
Performing Location:
MAYO Laboratory
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-31-0774-01

Order Name:
Lyme Disease Antibody, Immunoblot (MAYO Lab-USA) **

 
 
Clinical Information:
Aids in the diagnosis of systemic Lyme disease.

Lyme disease exhibits a variety of symptoms that may be confused with immune and inflammatory disorders. Inflammation around the tick bite causes skin lesions. Erythema chronicum migrans (ECM), a unique expanding skin lesion with central clearing that results in a ring-like appearance, is the first stage of the disease. Any of the following clinical manifestations may be present in patients with Lyme disease: arthritis, neurological or cardiac disease, or skin lesions. Neurologic and cardiac symptoms may appear with stage 2 and arthritic symptoms with stage 3 of Lyme disease. In some cases, a definitive distinction between stages is not always seen. Further, secondary symptoms may occur even though the patient does not recall having a tick bite or a rash.

The Second National Conference on the Serologic Diagnosis of Lyme Disease (1994) recommended that laboratories use a 2-test approach for the serologic diagnosis of Lyme disease. Accordingly, specimens are first tested by the more sensitive EIA. An immunoblot assay is used to supplement positive or equivocal Lyme (EIA). An immunoblot identifies the specific proteins to which the patient's antibodies bind. Although there are no proteins that specifically diagnose B burgdorferi infection, the number of proteins recognized in the immunoblot assay is correlated with diagnosis.

 
Reference Value:
IgG: Negative
IgM: Negative
 
Interpretation:
IgM:
IgM antibodies to Borrelia burgdorferi may be detectable within 1 to 2 weeks following the tick bite; they usually peak during the third to sixth week after disease onset, and then demonstrate a gradual decline over a period of months. IgM antibody may persist for months following completion of treatment. IgM antibody results against B burgdorferi should only be considered during the 30 days following exposure and symptom onset.

Negative specimens typically demonstrate antibodies to fewer than 2 of the 3 significant B burgdorferi proteins. Additional specimens should be submitted in 2 to 3 weeks if B burgdorferi exposure has not been ruled out.

IgG:
IgG antibodies to B burgdorferi can be detected approximately 2 weeks after onset of disease and can remain detectable for months to years following completion of therapy.

Normal specimens and false-positive EIA specimens generally have antibodies to 4 or fewer proteins. Except for early patients, antibodies from patients with Lyme disease generally bind to 5 or more proteins.
 
Clinical Reference:
www.mayocliniclabs.com (Retrieved: 30 Jun 2020)